1. Home
  2. SOPH vs RZLT Comparison

SOPH vs RZLT Comparison

Compare SOPH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

N/A

Current Price

$7.07

Market Cap

462.3M

Sector

Health Care

ML Signal

N/A

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

N/A

Current Price

$3.84

Market Cap

471.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOPH
RZLT
Founded
2011
2010
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.3M
471.0M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
SOPH
RZLT
Price
$7.07
$3.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$9.75
★ $9.80
AVG Volume (30 Days)
524.7K
★ 1.5M
Earning Date
11-03-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.25
N/A
Revenue Next Year
$24.62
$2,214.20
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.83
$1.07
52 Week High
$8.98
$11.46

Technical Indicators

Market Signals
Indicator
SOPH
RZLT
Relative Strength Index (RSI) 44.36 43.44
Support Level $4.58 $3.58
Resistance Level $8.80 $4.09
Average True Range (ATR) 0.47 0.30
MACD 0.06 0.01
Stochastic Oscillator 44.75 36.47

Price Performance

Historical Comparison
SOPH
RZLT

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

Share on Social Networks: